Chemical industry – Page 107
-
Opinion
Formulation chemist friction
Derek Lowe wonders where we'd be without the formulation chemists
-
Business
Business roundup: July 2009
Dow Corning unleashes innovation US silicone-materials maker Dow Corning is transforming its business strategy to focus on innovations in sustainability, efficiency and alternative energy. Even though the company has managed to stay profitable during the current economic downturn, which has seen many of its competitors struggle, Dow Corning has decided ...
-
Opinion
Collaborative compromise
Derek Lowe wonders about pharmaceutical companies' motives for collaboration
-
Business
Business roundup: June 2009
Animal testing amendments The European parliament has voted in favour of ’watering down’ its directive on the protection of animals used for scientific purposes - enabling researchers to continue conducting animal experiments to assess the safety of new drugs and chemicals. Last year, the European Commission proposed a range of ...
-
Opinion
Prescription unknowns
Derek Lowe considers what we think we know about how drugs work once we've taken them
-
Business
Business roundup: May 2009
Sanofi splashes the cash in Latin America Sanofi aims to be South America’s number one Sanofi-Aventis has gone on a South American shopping spree, buying two generics companies within the space of a week - and in the process has become Latin America’s leading generics manufacturer. On ...
-
Opinion
Stick to the steps
Derek Lowe considers the problems of addressing drug development out of sequence
-
Business
Business roundup: April 2009
Merger goes ahead as Dow, Rohm and Haas settle dispute Dow Chemical has finally agreed to complete the acquisition of speciality materials firm Rohm and Haas in a $15.3 billion (?11 billion) deal after the two firms settled their dispute over the planned merger. The takeover, which will create the ...
-
Opinion
A new wave of consolidation
Derek Lowe worries that mergers are upsetting the balance of the pharmaceutical ecosystem
-
Business
Business roundup: March 2009
Pfizer’s Wyeth injection Source: © AP PHOTOS Jeffrey Kindler, Pfizer’s CEO, explains the merger Pfizer has agreed to pay $68 billion (?48.3 billion) for rival US biopharmaceutical firm Wyeth, gaining access to its rich product portfolio and promising pipeline of experimental drugs. Pfizer hopes Wyeth’s products ...
-
Opinion
Cutting-edge technology for cutting-edge results?
How important is it to have the best equipped lab, wonders Derek Lowe
-
Business
Business roundup: February 2009
Dow’s Rohm and Haas deal on the rocks Despite having cleared European regulatory hurdles, Dow’s takeover of Rohm and Haas is hanging in the balance after state-owned Kuwait Petroleum Company (KPC) scuttled their $17.4 billion (£11.9 billion) K-Dow joint venture deal just days before it was set to close. ...
-
Business
Business roundup: January 2009
EU slams pharma delaying tactics Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market. It says that such practices cost EU taxpayers €3 billion between 2000 and 2007. The accusations come in a preliminary report on the Commission’s inquiry ...
-
Business
Business roundup: December 2008
GSK snaps up hepatitis expert In a bid to strengthen its position in the race to develop new hepatitis therapies, UK pharma giant GlaxoSmithKline (GSK) has agreed to buy Genelabs Technologies in a deal worth $57 million (£35 million). Source: © ISM / Science Photo Library Liver cells ...
-
Business
Business roundup: November 2008
Huntsman wins Hexion court fight Huntsman has won its legal battle to force Hexion to honour its $10.6 billion (?5.4 billion) takeover deal, originally agreed in July 2007. In June 2008, Hexion declared that it was taking legal action in a bid to back out of the deal, claiming that ...
-
Business
Business roundup: October 2008
BASF to buy Ciba Struggling Swiss speciality chemicals group Ciba has agreed to a SF6.1 billion (£3 billion) takeover deal by Germany’s BASF. Source: © AP PHOTOS Jurgen Hambrecht of BASF and Armin Meyer of Ciba On 15 September BASF announced its offer to buy Ciba shares ...